AbbVie Reports IMBRUVICA Phase 3 Combination Data With Obinutuzumab Shows Significant Improvement In Progression-Free Survival Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab In Lymphocytic Leukemia And Small Lymphocytic Lymphoma